Drug intelligence / Profile preview

ascorbic acid + temozolomide

Development stage: Unknown
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

A combination therapy consisting of high-dose ascorbic acid (vitamin C) and temozolomide, primarily investigated for the treatment of glioblastoma and other high-grade gliomas. High-dose ascorbic acid appears to induce cytotoxicity and oxidative stress selectively in malignant cells, potentially enhancing the DNA-damaging effects of temozolomide through mechanisms mediated by redox-active iron. This combination is typically administered with ascorbic acid given intravenously at high doses while temozolomide is administered orally, often alongside radiation therapy.

Other names: ascorbic acid + temozolomidevitamin C + temozolomide

Targets

DNATET1 (Methylcytosine dioxygenase TET1)

Beyond the preview

Go deeper on ascorbic acid + temozolomide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ascorbic acid + temozolomide.

Explore the full profile